Sanofi: fast-track procedure granted for Dupixent
(CercleFinance.com) - Sanofi announced on Monday morning that the FDA has granted Breakthrough Therapy designation (allowing it to benefit from a fast-track procedure) to Dupixent, for the treatment of eosinophilic esophagitis.
"Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE). There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients' ability to swallow and eat," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE). There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients' ability to swallow and eat," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.